Identification of candidate biomarkers using the Experion™ automated electrophoresis system in serum samples from ovarian cancer patients

Abstract

Abstract. Ovarian cancer is the most common cause of diseaserelated death in women globally. Detection of ovarian cancer using new biomarkers is necessary for early diagnosis. To date, there have been no obvious biomarkers for ovarian cancer detection in the incipient stage. In this study, we discovered potential diagnostic serological biomarkers for ovarian cancer using the Experion™ automated electrophoresis system. Sera from 14 healthy women and 84 ovarian cancer patients at stages I-IV were applied to the Experion to compare the protein expression levels. To examine the protein expression pattern of Experion data, proteins in the samples were resolved using 10 and 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and visualized by silver staining. The candidate biomarkers elevated in ovarian cancer were purified and determined using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. α-2-macroglobulin (173.7 kDa), ceruloplasmin (147 kDa), inter-α-trypsin inhibitor family heavy chain-related protein (126 kDa), C-1 inhibitor (115.2 kDa) and hemoglobin α/β (14.4 kDa were overexpressed in the ovarian cancer sera. This study documents a novel way to measure ovarian cancer or cancer-related proteins for biomarkers using the Experion assay system, which should be easily adaptable for high-throughput diagnosis to establish databases of ovarian cancer for clinical applications.

Glycoproteomic Analysis of Malignant Ovarian Cancer Ascites Fluid Identifies Unusual Glycopeptides

“…Because proteomic analysis of Asc1 samples was conducted separate from those of Asc412 and SS, which were analyzed together, the Asc1 results are shown in separate bar graphs from those of Asc412 and SS (determined using Scaffold v4). Proteins used for the figures were selected because all have previous reports in the literature connecting them to OC (haptoglobin, fibronectin, interalpha-trypsin inhibitor, clusterin, ceruloplasmin, alpha-1-antitrypsin, and hemopexin) 37 or were enriched in the OC ascites samples (lumican, fibulin, alpha-1-antichymotrypsin).…”

“…Interalpha-trypsin inhibitors consist of three or four heavy chains (interalpha-trypsin inhibitor heavy chains: H1, H2, H3, and H4) that combine with one light chain (AMBP or SPINT2) to function together as a covalent protein–glycosaminoglycan–protein complex to act as a protease inhibitor as part of an inflammatory response . Interalpha-trypsin inhibitors (ITIH) proteins, especially ITIH4 and ITIH1, have been previously reported in OC. ,, The interalpha-trypsin inhibitor heavy chains H1, H2, and H3 were detected in Asc1, Asc412, and SS samples, but ITH4 was not detected in Asc1 samples (Figure C). ITIH1 was enriched 4-fold in asc1-ConA and 6-fold in Asc1-WGA, 91-fold in Asc412-ConA and 81-fold in Asc412-WGA.…”

“…38 Interalphatrypsin inhibitors (ITIH) proteins, especially ITIH4 and ITIH1, have been previously reported in OC. 37,39,40 The interalpha-trypsin inhibitor heavy chains H1, H2, and H3 were detected in Asc1, Asc412, and SS samples, but ITH4 was not detected in Asc1 samples (Figure 6C). ITIH1 was enriched 4fold in asc1-ConA and 6-fold in Asc1-WGA, 91-fold in Asc412-ConA and 81-fold in Asc412-WGA.…”

Integrating Multi-Omics for Uncovering the Architecture of Cross-Talking Pathways in Breast Cancer

“…The pathway “Complement and coagulation cascades” cross-talk with “Pathway in cancer_1” through the interaction of leaders (A2M and PDGFRA) with linkers (PDGFA), and ultimately result in sustained angiogenesis (Figure 6A). Both A2M and PDGFRA with underexpression and somatic mutation can lead to the cancer development [43], [44]. Also, PDGFA was more frequently expressed in breast tumors [45].…”

SalivaPRINT Toolkit – Protein profile evaluation and phenotype stratification

“…Listeria monocytogenes in foods [13] and to measure ovarian cancer or cancerrelated proteins biomarkers in serum [14], however the methodology followed for result processing was to manually select individuals and check which molecular weights were different according to the individual's conditions.…”